Flatiron's research at SABCS 2025 unlocks breast cancer insights through integrated data, analytics, and expertise.
Flatiron Health today announced its presence at the San Antonio Breast Cancer Symposium (SABCS) happening from December 9-12, 2025, in San Antonio, Texas. Flatiron's real-world data and research capabilities are featured across multiple acceptances, including three spotlight presentations and four poster presentations that leverage the breadth of Flatiron’s breast cancer solutions.
"Breast cancer is the most common cancer in women worldwide , and every patient's journey raises critical questions—about treatment effectiveness, biomarker-driven approaches, clinical outcomes, and real-world access," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "At Flatiron, we've built a comprehensive, integrated ecosystem of breast cancer solutions that serve every stage of the oncology development life cycle and our research at SABCS demonstrates that when you have the right data infrastructure, analytics, and clinical expertise working together, you can answer virtually any question about breast cancer care and outcomes.”
Research highlights include:
- A Spotlight poster presentation leveraging the Flatiron Health–Caris Life Sciences Clinical-Molecular Database, the largest and most robust multimodal dataset of its kind, to identify key genetic alterations and expression changes linked to CDK4/6i treatment resistance.
- A Spotlight poster presentation utilizing large language models to explore the real-world use of GLP-1 medications among breast cancer patients and their potential impact on treatment outcomes.
- Multiple posters using Flatiron’s Panoramic breast cancer dataset to answer critical research questions on treatment patterns and the effectiveness of novel treatments in improving overall survival and progression-free survival in large, representative patient cohorts.
Learn more about our presence on Flatiron.com and follow Flatiron Health on X and LinkedIn for more updates from #SABCS25.
Abstracts and Poster Presentations
Personalized acquired CDK4/6i resistance: Associations with baseline characteristics like obesity in real-world (RW) clinical-multiomics data
Spotlight Poster Presentation
Kristin M. Zimmerman Savill, Lilia Bouzit, Noelle Liao, Cheryl Cho-Phan, Simon Papillon-Cavanagh
Author Affiliations: Caris Life Sciences, Flatiron Health
Presentation Number: PD3-02
Poster Spotlight 3: Emerging Paradigms of CDK Inhibitor and Antibody Drug Conjugate Resistance in Metastatic Breast Cancer
Presentation Date/Time: Wednesday, December 10, 2025, 7:33 AM - 7:36 AM
Location: 302 ABC
Racial/ethnic inequities in access to novel therapies and outcomes in triple negative breast cancer
Spotlight Poster Presentation
Olive M. Mbah, Gene G. Ho, Catherine Keane, Aaron Dolor, Cleo Ryals
Presentation Number: PD1-06
Poster Spotlight 1: Addressing breast cancer disparities and treatment related toxicities
Presentation Date/Time: Wednesday, December 10, 2025, 7:45 AM - 7:48 AM
Location: Hemisfair 3
Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer
Spotlight Poster Presentation
Cleo A. Ryals, Auriane Blarre, Blythe Adamson, Daniel Bower, Gene G. Ho, Olive Mbah, Selina Radlein, Erin Fidyk, Fatima Cody Stanford, Aaron B. Cohen
Author Affiliations: Massachusetts General Hospital, Flatiron Health
Presentation Number: PD8-08
Poster Spotlight 8: Beyond the Scale- Obesity and GLP-1 Therapies in Breast Cancer
Presentation Date/Time: Thursday, December 11, 2025, 8:03 AM - 8:06 AM
Location: 221 ABC
Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2– metastatic breast cancer (MBC)
Hope M. Rugo, Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Paul Cottu, Marc Thill, Giuseppe Curigliano
Author Affiliations: City of Hope Comprehensive Cancer Center, UPMC Hillman Cancer Center, The University of Texas MD Anderson Cancer Center, Pfizer, Université Paris Cité, Agaplesion Markus Krankenhaus, University of Milano, European Institute of Oncology, Flatiron Health
Presentation Number: PS1-11-10
Poster Session 1: Wednesday, December 10, 2025, 12:30 PM–2:00 PM
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024
Jane Meisel, Tim Pham, Clara Chen, Ayush Kris, James Roose
Author Affiliations: Emory Winship Cancer Institute, AstraZeneca, Flatiron Health
Presentation Number: PS2-02-04
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021–2025)
Sagar Sardesai, Meng Ru, Xinran Ma, Catherine Keane, Jingru Wang, Miguel Miranda, Xiaoqing Xu, Claudine Isaacs
Author Affiliations: The Ohio State University Comprehensive Cancer Center, Lombardi Comprehensive Cancer Center, AstraZeneca, Flatiron Health
Presentation Number: PS2-02-03
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in patients with HR+/HER2− metastatic breast cancer (MBC) who are overweight/obese
Adam Brufsky, Neil M. Iyengar, Xianchen Liu, Benjamin Li, Doris Makari, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Vandana G. Abramson, Rachel M. Layman, Giuseppe Curigliano
Author Affiliations: UPMC Hillman Cancer Center, Emory University School of Medicine, Pfizer, Vanderbilt University Medical Center, The University of Texas MD Anderson Cancer Center, University of Milano, European Institute of Oncology, Flatiron Health
Presentation Number: PS2-04-12
Poster Session 2: Wednesday, December 10, 2025, 5:00 PM - 6:30 PM
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
About Panoramic Data
Panoramic data is Flatiron's foundational real-world data, flexibly designed to meet the needs of biopharma’s evolving research priorities with biomarker depth, scaled outcomes, and longitudinal data across 5M+ patients. Panoramic data is a comprehensive data solution that spans disease settings and supports assessments of high priority subgroups of interest. Flatiron offers Panoramic data across solid tumors and hematologic malignancies to maximize use cases across oncology portfolios
Contact
Nina Toor
press@flatiron.com
